KPRX (Kiora Pharmaceuticals) Beginning Cash Position: $8.70 Mil (As of Mar. 2026)


KPRX Kiora Pharmaceuticals Inc KPRX
34 GF Score
Price $2.46
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Beginning Cash Position?

Kiora Pharmaceuticals KPRX -2.38% 34 Beginning Cash Position is $8.70 Mil as of Mar. 2026. GuruFocus rates KPRX with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Kiora Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2026 was $8.70 Mil.

Kiora Pharmaceuticals's quarterly Beginning Cash Position increased from Sep. 2025 ($1.03 Mil) to Dec. 2025 ($5.51 Mil) and increased from Dec. 2025 ($5.51 Mil) to Mar. 2026 ($8.70 Mil).

Kiora Pharmaceuticals's annual Beginning Cash Position declined from Dec. 2023 ($6.01 Mil) to Dec. 2024 ($2.46 Mil) but then increased from Dec. 2024 ($2.46 Mil) to Dec. 2025 ($3.80 Mil).

Kiora Pharmaceuticals Beginning Cash Position Related Terms

Kiora Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Kiora Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals Beginning Cash Position Chart

Kiora Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.23 7.90 6.01 2.46 3.80

Kiora Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.80 3.78 1.03 5.51 8.70
KPRX
34GF Score
Kiora Pharmaceuticals Inc KPRX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $8.70 Mil mean?
Kiora Pharmaceuticals (KPRX) has a Beginning Cash Position of $8.70 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Kiora Pharmaceuticals and its competitors.
Is Kiora Pharmaceuticals' Beginning Cash Position too high?
Kiora Pharmaceuticals' current Beginning Cash Position is $8.70 Mil. Overall, Kiora Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' Beginning Cash Position compare to PHIO and PBM?
Kiora Pharmaceuticals' Beginning Cash Position of $8.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Kiora Pharmaceuticals and its competitors. Kiora Pharmaceuticals's current Beginning Cash Position is $8.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (KPRX) has a current Beginning Cash Position of $8.70 Mil. The current Beginning Cash Position is $8.70 Mil. Kiora Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Kiora Pharmaceuticals (KPRX), the current Beginning Cash Position is $8.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kiora Pharmaceuticals Business Description

Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
34GF Score

Get the complete analysis for KPRX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.46
Price